Minerva Neurosciences, Inc. (Nasdaq: NERV) 77.5% HIGHER; announced that results from a Primomed (use of PRIMate MOdels to support translational MEDicine) non-human primate study showed that treatment with an analog of MIN-301, the company’s investigational neuregulin-1 compound, resulted in improvements in a range of symptoms associated with Parkinson’s disease in primates. MIN-301 is a recombinant form of the neuregulin-1β1 extracellular domain. The analog used in the Primomed study differs from MIN-301 by a single amino acid.
Cyberonics (NASDAQ: CYBX) 8.3% LOWER; announced the receipt of a decision from the Departmental Appeals Board (DAB) of the Department of Health and